Apyx Medical Corporation (NASDAQ:APYX) Given Consensus Rating of “Moderate Buy” by Analysts

Apyx Medical Corporation (NASDAQ:APYX) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $6.60.

A number of brokerages recently weighed in on APYX. HC Wainwright initiated coverage on shares of Apyx Medical in a research report on Monday, July 13th. They set a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th. Finally, Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th.

Institutional Trading of Apyx Medical

Several large investors have recently modified their holdings of APYX. Nantahala Capital Management LLC purchased a new stake in Apyx Medical during the second quarter valued at $14,683,414. AIGH Capital Management LLC purchased a new position in Apyx Medical in the second quarter worth about $5,066,000. BlackRock Inc. purchased a new position in Apyx Medical in the second quarter worth about $2,519,000. Sei Investments Co. grew its stake in shares of Apyx Medical by 298.6% during the 1st quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after purchasing an additional 448,174 shares during the period. Finally, Informed Momentum Co LLC bought a new stake in shares of Apyx Medical during the 4th quarter valued at about $863,000. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Price Performance

Shares of NASDAQ:APYX opened at $3.05 on Wednesday. The company has a debt-to-equity ratio of 3.19, a quick ratio of 4.53 and a current ratio of 5.68. The firm has a market cap of $128.47 million, a price-to-earnings ratio of -15.25 and a beta of 1.32. The business has a 50-day simple moving average of $3.83 and a two-hundred day simple moving average of $3.83. Apyx Medical has a fifty-two week low of $1.70 and a fifty-two week high of $5.08.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%. The firm had revenue of $13.88 million for the quarter, compared to the consensus estimate of $13.18 million. On average, analysts expect that Apyx Medical will post -0.25 earnings per share for the current year.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.